GUT -期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=502560, encodeId=ecad502560cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：今年IF会高于11，明年很可能12-13, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Apr 25 20:00:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498066, encodeId=336349806636, content=我们实验室最近一篇,Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3.Gut. 2013 Aug;62(8):1204-13. 感觉没有想象中的难.需要完整性!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Jul 24 17:30:00 CST 2013, time=2013-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497891, encodeId=493d49e891ea, content=秒拒，两天后回复，建议转投其它杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=246484336, createdName=operater001, createdTime=Mon Jul 15 00:02:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=493640, encodeId=58eb4936402c, content=要求很严，秒据……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=444, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Jan 26 14:57:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490508, encodeId=6d64490508ed, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Gut aims to publish original articles describing novel mechanisms of disease and new management strategies, both diagnostic and therapeutic, likely to impact on clinical practice within the foreseeable future. 8% for original research submitted in 2011 一审一般两周以内。 接收后刊登时间： 28 days (online) 5 months (print), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4b0939285, createdName=ppswppp, createdTime=Tue Sep 11 12:00:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490242, encodeId=348f490242e7, content=投稿命中率:5.0 经验分享：喵嘞个咪，胃肠病学顶尖期刊，难度不是一般的大！！！目前华人第一作者的只有81篇，排除港澳台的第一单位，中国大陆仅10余篇左右！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 28 10:30:00 CST 2012, time=2012-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485889, encodeId=0dec4858899e, content=审稿速度:2.0 经验分享：难度很大，文章一定要有创新性和潜在的临床实用价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Dec 14 20:18:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816027, encodeId=811381602ec9, content=审稿费不需要，但是需要彩图版免费，可以申请不彩打，偏重胃肠道疾病的临床方面的问题，水平要求好高呀，编辑要求的水平就很高，运气很重要！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85575414075, createdName=ms2798897682501839, createdTime=Wed Sep 07 09:33:00 CST 2011, time=2011-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483649, encodeId=4b6c483649c4, content=发表难度有点大，投稿前最好慎重选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jul 26 22:10:00 CST 2011, time=2011-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469746, encodeId=f23e469e465e, content=去年投了一次,3周被拒,不过速度还行吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=466, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gut, createdTime=Tue Dec 15 14:56:00 CST 2009, time=2009-12-15, status=1, ipAttribution=)]

2014-04-25 匿名用户

审稿速度:1.0 | 投稿命中率:5.0
经验分享：今年IF会高于11，明年很可能12-13

390 0

[GetPortalCommentsPageByObjectIdResponse(id=502560, encodeId=ecad502560cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：今年IF会高于11，明年很可能12-13, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Apr 25 20:00:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498066, encodeId=336349806636, content=我们实验室最近一篇,Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3.Gut. 2013 Aug;62(8):1204-13. 感觉没有想象中的难.需要完整性!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Jul 24 17:30:00 CST 2013, time=2013-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497891, encodeId=493d49e891ea, content=秒拒，两天后回复，建议转投其它杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=246484336, createdName=operater001, createdTime=Mon Jul 15 00:02:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=493640, encodeId=58eb4936402c, content=要求很严，秒据……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=444, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Jan 26 14:57:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490508, encodeId=6d64490508ed, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Gut aims to publish original articles describing novel mechanisms of disease and new management strategies, both diagnostic and therapeutic, likely to impact on clinical practice within the foreseeable future. 8% for original research submitted in 2011 一审一般两周以内。 接收后刊登时间： 28 days (online) 5 months (print), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4b0939285, createdName=ppswppp, createdTime=Tue Sep 11 12:00:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490242, encodeId=348f490242e7, content=投稿命中率:5.0 经验分享：喵嘞个咪，胃肠病学顶尖期刊，难度不是一般的大！！！目前华人第一作者的只有81篇，排除港澳台的第一单位，中国大陆仅10余篇左右！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 28 10:30:00 CST 2012, time=2012-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485889, encodeId=0dec4858899e, content=审稿速度:2.0 经验分享：难度很大，文章一定要有创新性和潜在的临床实用价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Dec 14 20:18:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816027, encodeId=811381602ec9, content=审稿费不需要，但是需要彩图版免费，可以申请不彩打，偏重胃肠道疾病的临床方面的问题，水平要求好高呀，编辑要求的水平就很高，运气很重要！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85575414075, createdName=ms2798897682501839, createdTime=Wed Sep 07 09:33:00 CST 2011, time=2011-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483649, encodeId=4b6c483649c4, content=发表难度有点大，投稿前最好慎重选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jul 26 22:10:00 CST 2011, time=2011-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469746, encodeId=f23e469e465e, content=去年投了一次,3周被拒,不过速度还行吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=466, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gut, createdTime=Tue Dec 15 14:56:00 CST 2009, time=2009-12-15, status=1, ipAttribution=)]

2013-07-24 匿名用户

我们实验室最近一篇,Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3.Gut. 2013 Aug;62(8):1204-13.
感觉没有想象中的难.需要完整性!

364 0

[GetPortalCommentsPageByObjectIdResponse(id=502560, encodeId=ecad502560cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：今年IF会高于11，明年很可能12-13, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Apr 25 20:00:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498066, encodeId=336349806636, content=我们实验室最近一篇,Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3.Gut. 2013 Aug;62(8):1204-13. 感觉没有想象中的难.需要完整性!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Jul 24 17:30:00 CST 2013, time=2013-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497891, encodeId=493d49e891ea, content=秒拒，两天后回复，建议转投其它杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=246484336, createdName=operater001, createdTime=Mon Jul 15 00:02:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=493640, encodeId=58eb4936402c, content=要求很严，秒据……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=444, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Jan 26 14:57:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490508, encodeId=6d64490508ed, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Gut aims to publish original articles describing novel mechanisms of disease and new management strategies, both diagnostic and therapeutic, likely to impact on clinical practice within the foreseeable future. 8% for original research submitted in 2011 一审一般两周以内。 接收后刊登时间： 28 days (online) 5 months (print), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4b0939285, createdName=ppswppp, createdTime=Tue Sep 11 12:00:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490242, encodeId=348f490242e7, content=投稿命中率:5.0 经验分享：喵嘞个咪，胃肠病学顶尖期刊，难度不是一般的大！！！目前华人第一作者的只有81篇，排除港澳台的第一单位，中国大陆仅10余篇左右！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 28 10:30:00 CST 2012, time=2012-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485889, encodeId=0dec4858899e, content=审稿速度:2.0 经验分享：难度很大，文章一定要有创新性和潜在的临床实用价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Dec 14 20:18:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816027, encodeId=811381602ec9, content=审稿费不需要，但是需要彩图版免费，可以申请不彩打，偏重胃肠道疾病的临床方面的问题，水平要求好高呀，编辑要求的水平就很高，运气很重要！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85575414075, createdName=ms2798897682501839, createdTime=Wed Sep 07 09:33:00 CST 2011, time=2011-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483649, encodeId=4b6c483649c4, content=发表难度有点大，投稿前最好慎重选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jul 26 22:10:00 CST 2011, time=2011-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469746, encodeId=f23e469e465e, content=去年投了一次,3周被拒,不过速度还行吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=466, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gut, createdTime=Tue Dec 15 14:56:00 CST 2009, time=2009-12-15, status=1, ipAttribution=)]

2013-07-15 operater001

秒拒，两天后回复，建议转投其它杂志。

417 0

[GetPortalCommentsPageByObjectIdResponse(id=502560, encodeId=ecad502560cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：今年IF会高于11，明年很可能12-13, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Apr 25 20:00:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498066, encodeId=336349806636, content=我们实验室最近一篇,Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3.Gut. 2013 Aug;62(8):1204-13. 感觉没有想象中的难.需要完整性!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Jul 24 17:30:00 CST 2013, time=2013-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497891, encodeId=493d49e891ea, content=秒拒，两天后回复，建议转投其它杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=246484336, createdName=operater001, createdTime=Mon Jul 15 00:02:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=493640, encodeId=58eb4936402c, content=要求很严，秒据……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=444, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Jan 26 14:57:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490508, encodeId=6d64490508ed, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Gut aims to publish original articles describing novel mechanisms of disease and new management strategies, both diagnostic and therapeutic, likely to impact on clinical practice within the foreseeable future. 8% for original research submitted in 2011 一审一般两周以内。 接收后刊登时间： 28 days (online) 5 months (print), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4b0939285, createdName=ppswppp, createdTime=Tue Sep 11 12:00:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490242, encodeId=348f490242e7, content=投稿命中率:5.0 经验分享：喵嘞个咪，胃肠病学顶尖期刊，难度不是一般的大！！！目前华人第一作者的只有81篇，排除港澳台的第一单位，中国大陆仅10余篇左右！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 28 10:30:00 CST 2012, time=2012-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485889, encodeId=0dec4858899e, content=审稿速度:2.0 经验分享：难度很大，文章一定要有创新性和潜在的临床实用价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Dec 14 20:18:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816027, encodeId=811381602ec9, content=审稿费不需要，但是需要彩图版免费，可以申请不彩打，偏重胃肠道疾病的临床方面的问题，水平要求好高呀，编辑要求的水平就很高，运气很重要！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85575414075, createdName=ms2798897682501839, createdTime=Wed Sep 07 09:33:00 CST 2011, time=2011-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483649, encodeId=4b6c483649c4, content=发表难度有点大，投稿前最好慎重选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jul 26 22:10:00 CST 2011, time=2011-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469746, encodeId=f23e469e465e, content=去年投了一次,3周被拒,不过速度还行吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=466, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gut, createdTime=Tue Dec 15 14:56:00 CST 2009, time=2009-12-15, status=1, ipAttribution=)]

2013-01-26 匿名用户

要求很严，秒据……

444 0

[GetPortalCommentsPageByObjectIdResponse(id=502560, encodeId=ecad502560cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：今年IF会高于11，明年很可能12-13, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Apr 25 20:00:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498066, encodeId=336349806636, content=我们实验室最近一篇,Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3.Gut. 2013 Aug;62(8):1204-13. 感觉没有想象中的难.需要完整性!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Jul 24 17:30:00 CST 2013, time=2013-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497891, encodeId=493d49e891ea, content=秒拒，两天后回复，建议转投其它杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=246484336, createdName=operater001, createdTime=Mon Jul 15 00:02:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=493640, encodeId=58eb4936402c, content=要求很严，秒据……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=444, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Jan 26 14:57:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490508, encodeId=6d64490508ed, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Gut aims to publish original articles describing novel mechanisms of disease and new management strategies, both diagnostic and therapeutic, likely to impact on clinical practice within the foreseeable future. 8% for original research submitted in 2011 一审一般两周以内。 接收后刊登时间： 28 days (online) 5 months (print), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4b0939285, createdName=ppswppp, createdTime=Tue Sep 11 12:00:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490242, encodeId=348f490242e7, content=投稿命中率:5.0 经验分享：喵嘞个咪，胃肠病学顶尖期刊，难度不是一般的大！！！目前华人第一作者的只有81篇，排除港澳台的第一单位，中国大陆仅10余篇左右！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 28 10:30:00 CST 2012, time=2012-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485889, encodeId=0dec4858899e, content=审稿速度:2.0 经验分享：难度很大，文章一定要有创新性和潜在的临床实用价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Dec 14 20:18:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816027, encodeId=811381602ec9, content=审稿费不需要，但是需要彩图版免费，可以申请不彩打，偏重胃肠道疾病的临床方面的问题，水平要求好高呀，编辑要求的水平就很高，运气很重要！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85575414075, createdName=ms2798897682501839, createdTime=Wed Sep 07 09:33:00 CST 2011, time=2011-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483649, encodeId=4b6c483649c4, content=发表难度有点大，投稿前最好慎重选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jul 26 22:10:00 CST 2011, time=2011-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469746, encodeId=f23e469e465e, content=去年投了一次,3周被拒,不过速度还行吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=466, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gut, createdTime=Tue Dec 15 14:56:00 CST 2009, time=2009-12-15, status=1, ipAttribution=)]

2012-09-11 ppswppp

审稿速度:1.0 | 投稿命中率:25.0
经验分享：Gut aims to publish original articles describing novel mechanisms of disease and new management strategies, both diagnostic and therapeutic, likely to impact on clinical practice within the foreseeable future.

8% for original research submitted in 2011

一审一般两周以内。

接收后刊登时间：
28 days (online)
5 months (print)

436 0

[GetPortalCommentsPageByObjectIdResponse(id=502560, encodeId=ecad502560cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：今年IF会高于11，明年很可能12-13, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Apr 25 20:00:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498066, encodeId=336349806636, content=我们实验室最近一篇,Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3.Gut. 2013 Aug;62(8):1204-13. 感觉没有想象中的难.需要完整性!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Jul 24 17:30:00 CST 2013, time=2013-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497891, encodeId=493d49e891ea, content=秒拒，两天后回复，建议转投其它杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=246484336, createdName=operater001, createdTime=Mon Jul 15 00:02:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=493640, encodeId=58eb4936402c, content=要求很严，秒据……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=444, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Jan 26 14:57:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490508, encodeId=6d64490508ed, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Gut aims to publish original articles describing novel mechanisms of disease and new management strategies, both diagnostic and therapeutic, likely to impact on clinical practice within the foreseeable future. 8% for original research submitted in 2011 一审一般两周以内。 接收后刊登时间： 28 days (online) 5 months (print), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4b0939285, createdName=ppswppp, createdTime=Tue Sep 11 12:00:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490242, encodeId=348f490242e7, content=投稿命中率:5.0 经验分享：喵嘞个咪，胃肠病学顶尖期刊，难度不是一般的大！！！目前华人第一作者的只有81篇，排除港澳台的第一单位，中国大陆仅10余篇左右！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 28 10:30:00 CST 2012, time=2012-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485889, encodeId=0dec4858899e, content=审稿速度:2.0 经验分享：难度很大，文章一定要有创新性和潜在的临床实用价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Dec 14 20:18:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816027, encodeId=811381602ec9, content=审稿费不需要，但是需要彩图版免费，可以申请不彩打，偏重胃肠道疾病的临床方面的问题，水平要求好高呀，编辑要求的水平就很高，运气很重要！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85575414075, createdName=ms2798897682501839, createdTime=Wed Sep 07 09:33:00 CST 2011, time=2011-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483649, encodeId=4b6c483649c4, content=发表难度有点大，投稿前最好慎重选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jul 26 22:10:00 CST 2011, time=2011-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469746, encodeId=f23e469e465e, content=去年投了一次,3周被拒,不过速度还行吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=466, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gut, createdTime=Tue Dec 15 14:56:00 CST 2009, time=2009-12-15, status=1, ipAttribution=)]

2012-08-28 匿名用户

投稿命中率:5.0
经验分享：喵嘞个咪，胃肠病学顶尖期刊，难度不是一般的大！！！目前华人第一作者的只有81篇，排除港澳台的第一单位，中国大陆仅10余篇左右！

385 0

[GetPortalCommentsPageByObjectIdResponse(id=502560, encodeId=ecad502560cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：今年IF会高于11，明年很可能12-13, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Apr 25 20:00:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498066, encodeId=336349806636, content=我们实验室最近一篇,Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3.Gut. 2013 Aug;62(8):1204-13. 感觉没有想象中的难.需要完整性!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Jul 24 17:30:00 CST 2013, time=2013-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497891, encodeId=493d49e891ea, content=秒拒，两天后回复，建议转投其它杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=246484336, createdName=operater001, createdTime=Mon Jul 15 00:02:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=493640, encodeId=58eb4936402c, content=要求很严，秒据……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=444, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Jan 26 14:57:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490508, encodeId=6d64490508ed, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Gut aims to publish original articles describing novel mechanisms of disease and new management strategies, both diagnostic and therapeutic, likely to impact on clinical practice within the foreseeable future. 8% for original research submitted in 2011 一审一般两周以内。 接收后刊登时间： 28 days (online) 5 months (print), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4b0939285, createdName=ppswppp, createdTime=Tue Sep 11 12:00:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490242, encodeId=348f490242e7, content=投稿命中率:5.0 经验分享：喵嘞个咪，胃肠病学顶尖期刊，难度不是一般的大！！！目前华人第一作者的只有81篇，排除港澳台的第一单位，中国大陆仅10余篇左右！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 28 10:30:00 CST 2012, time=2012-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485889, encodeId=0dec4858899e, content=审稿速度:2.0 经验分享：难度很大，文章一定要有创新性和潜在的临床实用价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Dec 14 20:18:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816027, encodeId=811381602ec9, content=审稿费不需要，但是需要彩图版免费，可以申请不彩打，偏重胃肠道疾病的临床方面的问题，水平要求好高呀，编辑要求的水平就很高，运气很重要！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85575414075, createdName=ms2798897682501839, createdTime=Wed Sep 07 09:33:00 CST 2011, time=2011-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483649, encodeId=4b6c483649c4, content=发表难度有点大，投稿前最好慎重选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jul 26 22:10:00 CST 2011, time=2011-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469746, encodeId=f23e469e465e, content=去年投了一次,3周被拒,不过速度还行吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=466, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gut, createdTime=Tue Dec 15 14:56:00 CST 2009, time=2009-12-15, status=1, ipAttribution=)]

2011-12-14 匿名用户

审稿速度:2.0
经验分享：难度很大，文章一定要有创新性和潜在的临床实用价值

357 0

[GetPortalCommentsPageByObjectIdResponse(id=502560, encodeId=ecad502560cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：今年IF会高于11，明年很可能12-13, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Apr 25 20:00:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498066, encodeId=336349806636, content=我们实验室最近一篇,Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3.Gut. 2013 Aug;62(8):1204-13. 感觉没有想象中的难.需要完整性!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Jul 24 17:30:00 CST 2013, time=2013-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497891, encodeId=493d49e891ea, content=秒拒，两天后回复，建议转投其它杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=246484336, createdName=operater001, createdTime=Mon Jul 15 00:02:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=493640, encodeId=58eb4936402c, content=要求很严，秒据……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=444, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Jan 26 14:57:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490508, encodeId=6d64490508ed, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Gut aims to publish original articles describing novel mechanisms of disease and new management strategies, both diagnostic and therapeutic, likely to impact on clinical practice within the foreseeable future. 8% for original research submitted in 2011 一审一般两周以内。 接收后刊登时间： 28 days (online) 5 months (print), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4b0939285, createdName=ppswppp, createdTime=Tue Sep 11 12:00:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490242, encodeId=348f490242e7, content=投稿命中率:5.0 经验分享：喵嘞个咪，胃肠病学顶尖期刊，难度不是一般的大！！！目前华人第一作者的只有81篇，排除港澳台的第一单位，中国大陆仅10余篇左右！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 28 10:30:00 CST 2012, time=2012-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485889, encodeId=0dec4858899e, content=审稿速度:2.0 经验分享：难度很大，文章一定要有创新性和潜在的临床实用价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Dec 14 20:18:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816027, encodeId=811381602ec9, content=审稿费不需要，但是需要彩图版免费，可以申请不彩打，偏重胃肠道疾病的临床方面的问题，水平要求好高呀，编辑要求的水平就很高，运气很重要！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85575414075, createdName=ms2798897682501839, createdTime=Wed Sep 07 09:33:00 CST 2011, time=2011-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483649, encodeId=4b6c483649c4, content=发表难度有点大，投稿前最好慎重选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jul 26 22:10:00 CST 2011, time=2011-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469746, encodeId=f23e469e465e, content=去年投了一次,3周被拒,不过速度还行吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=466, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gut, createdTime=Tue Dec 15 14:56:00 CST 2009, time=2009-12-15, status=1, ipAttribution=)]

2011-09-07 ms2798897682501839

审稿费不需要，但是需要彩图版免费，可以申请不彩打，偏重胃肠道疾病的临床方面的问题，水平要求好高呀，编辑要求的水平就很高，运气很重要！

55 0

[GetPortalCommentsPageByObjectIdResponse(id=502560, encodeId=ecad502560cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：今年IF会高于11，明年很可能12-13, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Apr 25 20:00:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498066, encodeId=336349806636, content=我们实验室最近一篇,Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3.Gut. 2013 Aug;62(8):1204-13. 感觉没有想象中的难.需要完整性!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Jul 24 17:30:00 CST 2013, time=2013-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497891, encodeId=493d49e891ea, content=秒拒，两天后回复，建议转投其它杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=246484336, createdName=operater001, createdTime=Mon Jul 15 00:02:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=493640, encodeId=58eb4936402c, content=要求很严，秒据……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=444, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Jan 26 14:57:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490508, encodeId=6d64490508ed, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Gut aims to publish original articles describing novel mechanisms of disease and new management strategies, both diagnostic and therapeutic, likely to impact on clinical practice within the foreseeable future. 8% for original research submitted in 2011 一审一般两周以内。 接收后刊登时间： 28 days (online) 5 months (print), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4b0939285, createdName=ppswppp, createdTime=Tue Sep 11 12:00:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490242, encodeId=348f490242e7, content=投稿命中率:5.0 经验分享：喵嘞个咪，胃肠病学顶尖期刊，难度不是一般的大！！！目前华人第一作者的只有81篇，排除港澳台的第一单位，中国大陆仅10余篇左右！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 28 10:30:00 CST 2012, time=2012-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485889, encodeId=0dec4858899e, content=审稿速度:2.0 经验分享：难度很大，文章一定要有创新性和潜在的临床实用价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Dec 14 20:18:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816027, encodeId=811381602ec9, content=审稿费不需要，但是需要彩图版免费，可以申请不彩打，偏重胃肠道疾病的临床方面的问题，水平要求好高呀，编辑要求的水平就很高，运气很重要！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85575414075, createdName=ms2798897682501839, createdTime=Wed Sep 07 09:33:00 CST 2011, time=2011-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483649, encodeId=4b6c483649c4, content=发表难度有点大，投稿前最好慎重选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jul 26 22:10:00 CST 2011, time=2011-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469746, encodeId=f23e469e465e, content=去年投了一次,3周被拒,不过速度还行吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=466, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gut, createdTime=Tue Dec 15 14:56:00 CST 2009, time=2009-12-15, status=1, ipAttribution=)]

2011-07-26 匿名用户

发表难度有点大，投稿前最好慎重选择

410 0

[GetPortalCommentsPageByObjectIdResponse(id=502560, encodeId=ecad502560cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：今年IF会高于11，明年很可能12-13, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Fri Apr 25 20:00:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=498066, encodeId=336349806636, content=我们实验室最近一篇,Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3.Gut. 2013 Aug;62(8):1204-13. 感觉没有想象中的难.需要完整性!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=364, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Jul 24 17:30:00 CST 2013, time=2013-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497891, encodeId=493d49e891ea, content=秒拒，两天后回复，建议转投其它杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=417, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=246484336, createdName=operater001, createdTime=Mon Jul 15 00:02:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=493640, encodeId=58eb4936402c, content=要求很严，秒据……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=444, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Jan 26 14:57:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490508, encodeId=6d64490508ed, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Gut aims to publish original articles describing novel mechanisms of disease and new management strategies, both diagnostic and therapeutic, likely to impact on clinical practice within the foreseeable future. 8% for original research submitted in 2011 一审一般两周以内。 接收后刊登时间： 28 days (online) 5 months (print), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4b0939285, createdName=ppswppp, createdTime=Tue Sep 11 12:00:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=490242, encodeId=348f490242e7, content=投稿命中率:5.0 经验分享：喵嘞个咪，胃肠病学顶尖期刊，难度不是一般的大！！！目前华人第一作者的只有81篇，排除港澳台的第一单位，中国大陆仅10余篇左右！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Aug 28 10:30:00 CST 2012, time=2012-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485889, encodeId=0dec4858899e, content=审稿速度:2.0 经验分享：难度很大，文章一定要有创新性和潜在的临床实用价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Dec 14 20:18:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816027, encodeId=811381602ec9, content=审稿费不需要，但是需要彩图版免费，可以申请不彩打，偏重胃肠道疾病的临床方面的问题，水平要求好高呀，编辑要求的水平就很高，运气很重要！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85575414075, createdName=ms2798897682501839, createdTime=Wed Sep 07 09:33:00 CST 2011, time=2011-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483649, encodeId=4b6c483649c4, content=发表难度有点大，投稿前最好慎重选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jul 26 22:10:00 CST 2011, time=2011-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469746, encodeId=f23e469e465e, content=去年投了一次,3周被拒,不过速度还行吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=466, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gut, createdTime=Tue Dec 15 14:56:00 CST 2009, time=2009-12-15, status=1, ipAttribution=)]

2009-12-15 gut

去年投了一次,3周被拒,不过速度还行吧

466 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务